MiNK Therapeutics, Inc. (INKT)
Market Cap | 30.91M |
Revenue (ttm) | n/a |
Net Income (ttm) | -20.59M |
Shares Out | 34.73M |
EPS (ttm) | -0.59 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 19,318 |
Open | 0.940 |
Previous Close | 0.916 |
Day's Range | 0.885 - 0.950 |
52-Week Range | 0.750 - 2.150 |
Beta | 0.05 |
Analysts | Strong Buy |
Price Target | 9.00 (+911.24%) |
Earnings Date | Aug 8, 2024 |
About INKT
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for INKT stock is "Strong Buy" and the 12-month stock price forecast is $9.0.
News
![](https://cdn.snapi.dev/images/v1/o/y/conf1-2463332.jpg)
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei...
![](https://cdn.snapi.dev/images/v1/o/l/press19-2443127.jpg)
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic...
![](https://cdn.snapi.dev/images/v1/z/n/press19-2429060.jpg)
MiNK Reports First Quarter 2024 Results
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic...
![](https://cdn.snapi.dev/images/v1/s/a/press5-2426659.jpg)
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic...
![](https://cdn.snapi.dev/images/v1/r/z/press13-2399389.jpg)
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogene...
![](https://cdn.snapi.dev/images/v1/s/r/press13-2361433.jpg)
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogene...
![](https://cdn.snapi.dev/images/v1/l/m/press3-2334802.jpg)
MiNK Reports Fourth Quarter and Year-End 2023 Results
NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogen...
![](https://cdn.snapi.dev/images/v1/1/w/press4-2312833.jpg)
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogene...
![](https://cdn.snapi.dev/images/v1/7/c/press13-2310759.jpg)
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model
![](https://cdn.snapi.dev/images/v1/z/u/press14-2250495.jpg)
MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei...
![](https://cdn.snapi.dev/images/v1/g/9/press9-2203270.jpg)
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
SAN DIEGO and NEW YORK and SINGAPORE, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ImmunoScape , a biotechnology company focused on the discovery and development of next-generation T cell receptor (TCR)-based th...
![](https://cdn.snapi.dev/images/v1/w/v/press6-2149304.jpg)
MiNK Therapeutics Reports Third Quarter 2023 Results
NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei...
![](https://cdn.snapi.dev/images/v1/v/o/press11-2139472.jpg)
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei...
![](https://cdn.snapi.dev/images/v1/b/i/press19-2127679.jpg)
MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update
NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei...
![](https://cdn.snapi.dev/images/v1/m/d/conf7-2079803.jpg)
MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogene...
![](https://cdn.snapi.dev/images/v1/v/x/conf10-2035831.jpg)
MiNK Therapeutics to Participate in September Investor Conferences
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic,...
![](https://cdn.snapi.dev/images/v1/k/g/press3-2016853.jpg)
MiNK Therapeutics Reports Second Quarter 2023 Results
- Randomized Phase 2 Trial in 2L Metastatic Gastric Cancer Planned to Launch at Memorial Sloan Kettering Cancer Center
![](https://cdn.snapi.dev/images/v1/u/k/press8-1994433.jpg)
MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update
NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic,...
![](https://cdn.snapi.dev/images/v1/4/y/press16-1901177.jpg)
MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference
NEW YORK, May 22, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic,...
![](https://cdn.snapi.dev/images/v1/a/0/press20-1897119.jpg)
MiNK's Novel FAP-CAR-iNKT Presented at ASGCT
NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic,...
![](https://cdn.snapi.dev/images/v1/g/f/press1-1884875.jpg)
MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic...
![](https://cdn.snapi.dev/images/v1/6/x/conf13-1857661.jpg)
MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogene...
![](https://cdn.snapi.dev/images/v1/t/h/press4-1842144.jpg)
MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogenei...
![](https://cdn.snapi.dev/images/v1/e/1/press13-1805640.jpg)
MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogene...
![](https://cdn.snapi.dev/images/v1/w/r/conf4-1797892.jpg)
MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting
– Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors